AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
The current AbbVie(ABBV) stock price is $282.57, with a market capitalization of 499.34B. The stock trades at a price-to-earnings (P/E) ratio of 77.57 and offers a dividend yield of 2.49%.
On 2026-10-14, AbbVie(ABBV) stock traded between a low of $275.52 and a high of $282.75. Shares are currently priced at $282.57, which is +2.6% above the low and -0.1% below the high.
AbbVie(ABBV) shares are trading with a volume of 507.98K, against a daily average of 5.41M.
During the past year, AbbVie(ABBV) stock moved between $190.75 at its lowest and $283.43 at its peak.
During the past year, AbbVie(ABBV) stock moved between $190.75 at its lowest and $283.43 at its peak.
ABBV News
Investing Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying Every big pharma company eventually watches its best-selling drug go generic...
Deciding between established drugmakers requires balancing current income with future growth. You might be weighing AbbVie Inc. (ABBV -2.40%) against Novo Nordi...
AbbVie (ABBV) announced new findings from the Phase 3 AFFIRM study evaluating a new option for induction treatment with Skyrizi in adults with moderately to sev...
Analyst ratings
75%
of 32 ratingsMore ABBV News
AbbVie has reported a cluster of positive clinical and regulatory updates across immunology, oncology and metabolic programs, including FDA Breakthrough Therapy...
On CNBC’s “Halftime Report Final Trades,” Stephen Weiss, chief investment officer and managing partner of Short Hills Capital Partners, picked Netflix, Inc. (NA...
Skyrizi and Rinvoq are growing fast, a blockbuster acquisition just closed, and the FDA handed AbbVie a fresh approval, yet the stock sits just shy of a price t...
AbbVie (ABBV) announced the presentation of 22 scientific abstracts from its market-leading inflammatory bowel disease, IBD, portfolio at the American College o...
AbbVie (ABBV +1.49%) has been a favorite for income investors since spinning off from Abbott Labs (ABT +1.13%) in 2013. For much of the past 13 years, the big d...
Dividend investors often focus first on yield, which can lead to an overly aggressive portfolio. For example, in the pharmaceutical sector, Pfizer (PFE +1.65%)...
has turned into a powerful long term winner for shareholders. With the stock now around US$276, the key issue is whether those cash flows can support the curren...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.